FLORA Ventures

FLORA Ventures, headquartered in Tel Aviv, is an early-stage fund organized around the convergence of food, wellness, and health. The thesis is that nutrition, metabolic health, and consumer wellness are increasingly inseparable from clinical care, and that the most interesting companies in the next decade will sit at that interface. For AI healthcare founders, the relevant slice of this thesis covers consumer health platforms, nutritional AI, metabolic disease management, and digital products that link diet, behavior, and physiological outcomes.

FLORA tends to back companies that combine consumer-facing experiences with serious data and clinical credibility. Pure consumer brands without a technology spine, traditional medical devices, and biotech are not core. The fund is most interested in software and tech-enabled services where AI personalizes nutrition or behavior at scale, where data partnerships with clinicians or labs strengthen the product, and where outcome claims can be substantiated rather than asserted in marketing copy.

Check sizes range from $250k to $1M at entry, typically at pre-seed and seed. FLORA participates in priced rounds and is comfortable as an early lead at small round sizes or as a co-investor in larger seeds. Geography is principally Israel, with companies expected to commercialize globally, often with the US as the first major market. Syndicate partners include other Israeli early-stage funds, US consumer and digital health specialists, and selected strategic investors in the food and wellness industries. Reserve strategy is meaningful for a fund of this size, and follow-on participation is expected when companies progress.

The team is small and active, with partners drawing on backgrounds in consumer, food, technology investing, and operations in adjacent industries. Engagement at the early stage is hands-on, with help focused on product positioning, brand, clinical advisory, and downstream financing.

Founders should approach FLORA with a clear articulation of why food, wellness, and health intersect inside the product, and what the data and clinical strategy looks like at meaningful scale. Introductions through portfolio CEOs, Israeli early-stage funds, or operators in the consumer wellness space are the most efficient path. The right time to engage is when the product is in market or near it, when early users or pilot partners exist, and when the team has begun to think seriously about defensibility. Founders pitching pure clinical software with no consumer angle, devices, or biotech are unlikely to fit. Companies whose only differentiation is brand without a technology backbone will struggle to clear diligence. For founders building genuinely tech-enabled consumer health products at the food, wellness, and metabolic care intersection, FLORA is among the more thesis-aligned early-stage partners in the Israeli ecosystem.